Dissolvable microarray patches of levodopa and carbidopa for Parkinson’s disease management

[Display omitted] Carbidopa and levodopa remain the established therapeutic standard for managing Parkinson’s disease. Nevertheless, their oral administration is hindered by rapid enzymatic degradation and gastrointestinal issues, limiting their efficacy, and necessitating alternative delivery metho...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of pharmaceutics and biopharmaceutics 2024-06, Vol.199, p.114304-114304, Article 114304
Hauptverfasser: Anjani, Qonita Kurnia, Moreno-Castellanos, Natalia, Li, Yaocun, Sabri, Akmal Hidayat Bin, Donnelly, Ryan F.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 114304
container_issue
container_start_page 114304
container_title European journal of pharmaceutics and biopharmaceutics
container_volume 199
creator Anjani, Qonita Kurnia
Moreno-Castellanos, Natalia
Li, Yaocun
Sabri, Akmal Hidayat Bin
Donnelly, Ryan F.
description [Display omitted] Carbidopa and levodopa remain the established therapeutic standard for managing Parkinson’s disease. Nevertheless, their oral administration is hindered by rapid enzymatic degradation and gastrointestinal issues, limiting their efficacy, and necessitating alternative delivery methods. This work presents a novel strategy employing dissolving microarray patches (MAPs) loaded with carbidopa and levodopa, formulated with Tween® 80 to improve their transdermal delivery. The fabricated MAPs demonstrated an acceptable mechanical strength, resisting pressures equivalent to manual human thumb application (32 N) onto the skin. Additionally, these MAPs exhibited an insertion depth of up to 650 µm into excised neonatal porcine skin. Ex vivo dermatokinetic studies could achieve delivery efficiencies of approximately 53.35 % for levodopa and 40.14 % for carbidopa over 24 h, demonstrating their significant potential in drug delivery. Biocompatibility assessments conducted on human dermal fibroblast cells corroborated acceptable cytocompatibility, confirming the suitability of these MAPs for dermal application. In conclusion, dissolving MAPs incorporating carbidopa and levodopa represent a promising alternative for improving the therapeutic management of Parkinson’s disease.
doi_str_mv 10.1016/j.ejpb.2024.114304
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3047941731</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0939641124001309</els_id><sourcerecordid>3047941731</sourcerecordid><originalsourceid>FETCH-LOGICAL-c351t-67b096d543dcd1d88518b3a7863730e08244645f3af2a64ceb5f32083903fed03</originalsourceid><addsrcrecordid>eNp9kLtOxDAQRS0EguXxAxQoJU0WO3YcR6JBvCUkKKBE1sSegJckDnZ2JTp-g9_jS8iyQEk1M9K5V5pDyD6jU0aZPJpNcdZX04xmYsqY4FSskQlTBU-5EGydTGjJy1QKxrbIdowzSqkocrVJtriSkudZNiGPZy5G3yygajBpnQkeQoC3pIfBPGNMfJ00uPDW95BAZxMDoXLfV-1DcgfhxXXRd5_vHzGxLiLEsQY6eMIWu2GXbNTQRNz7mTvk4eL8_vQqvbm9vD49uUkNz9mQyqKipbS54NZYZpXKmao4FEryglOkKhNCirzmUGcghcFq3DOqeEl5jZbyHXK46u2Df51jHHTrosGmgQ79POpRTVEKVnA2otkKHV-NMWCt--BaCG-aUb3Uqmd6qVUvteqV1jF08NM_r1q0f5FfjyNwvAJw_HLhMOhoHHYGrQtoBm29-6__C7ETidc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3047941731</pqid></control><display><type>article</type><title>Dissolvable microarray patches of levodopa and carbidopa for Parkinson’s disease management</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Anjani, Qonita Kurnia ; Moreno-Castellanos, Natalia ; Li, Yaocun ; Sabri, Akmal Hidayat Bin ; Donnelly, Ryan F.</creator><creatorcontrib>Anjani, Qonita Kurnia ; Moreno-Castellanos, Natalia ; Li, Yaocun ; Sabri, Akmal Hidayat Bin ; Donnelly, Ryan F.</creatorcontrib><description>[Display omitted] Carbidopa and levodopa remain the established therapeutic standard for managing Parkinson’s disease. Nevertheless, their oral administration is hindered by rapid enzymatic degradation and gastrointestinal issues, limiting their efficacy, and necessitating alternative delivery methods. This work presents a novel strategy employing dissolving microarray patches (MAPs) loaded with carbidopa and levodopa, formulated with Tween® 80 to improve their transdermal delivery. The fabricated MAPs demonstrated an acceptable mechanical strength, resisting pressures equivalent to manual human thumb application (32 N) onto the skin. Additionally, these MAPs exhibited an insertion depth of up to 650 µm into excised neonatal porcine skin. Ex vivo dermatokinetic studies could achieve delivery efficiencies of approximately 53.35 % for levodopa and 40.14 % for carbidopa over 24 h, demonstrating their significant potential in drug delivery. Biocompatibility assessments conducted on human dermal fibroblast cells corroborated acceptable cytocompatibility, confirming the suitability of these MAPs for dermal application. In conclusion, dissolving MAPs incorporating carbidopa and levodopa represent a promising alternative for improving the therapeutic management of Parkinson’s disease.</description><identifier>ISSN: 0939-6411</identifier><identifier>EISSN: 1873-3441</identifier><identifier>DOI: 10.1016/j.ejpb.2024.114304</identifier><identifier>PMID: 38663522</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Administration, Cutaneous ; Animals ; Antiparkinson Agents - administration &amp; dosage ; Antiparkinson Agents - pharmacology ; Carbidopa ; Carbidopa - administration &amp; dosage ; Dissolving microarray patches ; Drug Combinations ; Drug Delivery Systems - methods ; Fibroblasts - drug effects ; Fibroblasts - metabolism ; Humans ; Levodopa ; Levodopa - administration &amp; dosage ; Microneedles ; Parkinson Disease - drug therapy ; Parkinson’s disease ; Skin - drug effects ; Skin - metabolism ; Skin Absorption - drug effects ; Swine ; Transdermal Patch</subject><ispartof>European journal of pharmaceutics and biopharmaceutics, 2024-06, Vol.199, p.114304-114304, Article 114304</ispartof><rights>2024</rights><rights>Copyright © 2024. Published by Elsevier B.V.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c351t-67b096d543dcd1d88518b3a7863730e08244645f3af2a64ceb5f32083903fed03</cites><orcidid>0000-0002-3732-4899 ; 0000-0003-2481-3164 ; 0000-0002-0766-4147</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0939641124001309$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,65309</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38663522$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Anjani, Qonita Kurnia</creatorcontrib><creatorcontrib>Moreno-Castellanos, Natalia</creatorcontrib><creatorcontrib>Li, Yaocun</creatorcontrib><creatorcontrib>Sabri, Akmal Hidayat Bin</creatorcontrib><creatorcontrib>Donnelly, Ryan F.</creatorcontrib><title>Dissolvable microarray patches of levodopa and carbidopa for Parkinson’s disease management</title><title>European journal of pharmaceutics and biopharmaceutics</title><addtitle>Eur J Pharm Biopharm</addtitle><description>[Display omitted] Carbidopa and levodopa remain the established therapeutic standard for managing Parkinson’s disease. Nevertheless, their oral administration is hindered by rapid enzymatic degradation and gastrointestinal issues, limiting their efficacy, and necessitating alternative delivery methods. This work presents a novel strategy employing dissolving microarray patches (MAPs) loaded with carbidopa and levodopa, formulated with Tween® 80 to improve their transdermal delivery. The fabricated MAPs demonstrated an acceptable mechanical strength, resisting pressures equivalent to manual human thumb application (32 N) onto the skin. Additionally, these MAPs exhibited an insertion depth of up to 650 µm into excised neonatal porcine skin. Ex vivo dermatokinetic studies could achieve delivery efficiencies of approximately 53.35 % for levodopa and 40.14 % for carbidopa over 24 h, demonstrating their significant potential in drug delivery. Biocompatibility assessments conducted on human dermal fibroblast cells corroborated acceptable cytocompatibility, confirming the suitability of these MAPs for dermal application. In conclusion, dissolving MAPs incorporating carbidopa and levodopa represent a promising alternative for improving the therapeutic management of Parkinson’s disease.</description><subject>Administration, Cutaneous</subject><subject>Animals</subject><subject>Antiparkinson Agents - administration &amp; dosage</subject><subject>Antiparkinson Agents - pharmacology</subject><subject>Carbidopa</subject><subject>Carbidopa - administration &amp; dosage</subject><subject>Dissolving microarray patches</subject><subject>Drug Combinations</subject><subject>Drug Delivery Systems - methods</subject><subject>Fibroblasts - drug effects</subject><subject>Fibroblasts - metabolism</subject><subject>Humans</subject><subject>Levodopa</subject><subject>Levodopa - administration &amp; dosage</subject><subject>Microneedles</subject><subject>Parkinson Disease - drug therapy</subject><subject>Parkinson’s disease</subject><subject>Skin - drug effects</subject><subject>Skin - metabolism</subject><subject>Skin Absorption - drug effects</subject><subject>Swine</subject><subject>Transdermal Patch</subject><issn>0939-6411</issn><issn>1873-3441</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kLtOxDAQRS0EguXxAxQoJU0WO3YcR6JBvCUkKKBE1sSegJckDnZ2JTp-g9_jS8iyQEk1M9K5V5pDyD6jU0aZPJpNcdZX04xmYsqY4FSskQlTBU-5EGydTGjJy1QKxrbIdowzSqkocrVJtriSkudZNiGPZy5G3yygajBpnQkeQoC3pIfBPGNMfJ00uPDW95BAZxMDoXLfV-1DcgfhxXXRd5_vHzGxLiLEsQY6eMIWu2GXbNTQRNz7mTvk4eL8_vQqvbm9vD49uUkNz9mQyqKipbS54NZYZpXKmao4FEryglOkKhNCirzmUGcghcFq3DOqeEl5jZbyHXK46u2Df51jHHTrosGmgQ79POpRTVEKVnA2otkKHV-NMWCt--BaCG-aUb3Uqmd6qVUvteqV1jF08NM_r1q0f5FfjyNwvAJw_HLhMOhoHHYGrQtoBm29-6__C7ETidc</recordid><startdate>202406</startdate><enddate>202406</enddate><creator>Anjani, Qonita Kurnia</creator><creator>Moreno-Castellanos, Natalia</creator><creator>Li, Yaocun</creator><creator>Sabri, Akmal Hidayat Bin</creator><creator>Donnelly, Ryan F.</creator><general>Elsevier B.V</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-3732-4899</orcidid><orcidid>https://orcid.org/0000-0003-2481-3164</orcidid><orcidid>https://orcid.org/0000-0002-0766-4147</orcidid></search><sort><creationdate>202406</creationdate><title>Dissolvable microarray patches of levodopa and carbidopa for Parkinson’s disease management</title><author>Anjani, Qonita Kurnia ; Moreno-Castellanos, Natalia ; Li, Yaocun ; Sabri, Akmal Hidayat Bin ; Donnelly, Ryan F.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c351t-67b096d543dcd1d88518b3a7863730e08244645f3af2a64ceb5f32083903fed03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Administration, Cutaneous</topic><topic>Animals</topic><topic>Antiparkinson Agents - administration &amp; dosage</topic><topic>Antiparkinson Agents - pharmacology</topic><topic>Carbidopa</topic><topic>Carbidopa - administration &amp; dosage</topic><topic>Dissolving microarray patches</topic><topic>Drug Combinations</topic><topic>Drug Delivery Systems - methods</topic><topic>Fibroblasts - drug effects</topic><topic>Fibroblasts - metabolism</topic><topic>Humans</topic><topic>Levodopa</topic><topic>Levodopa - administration &amp; dosage</topic><topic>Microneedles</topic><topic>Parkinson Disease - drug therapy</topic><topic>Parkinson’s disease</topic><topic>Skin - drug effects</topic><topic>Skin - metabolism</topic><topic>Skin Absorption - drug effects</topic><topic>Swine</topic><topic>Transdermal Patch</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Anjani, Qonita Kurnia</creatorcontrib><creatorcontrib>Moreno-Castellanos, Natalia</creatorcontrib><creatorcontrib>Li, Yaocun</creatorcontrib><creatorcontrib>Sabri, Akmal Hidayat Bin</creatorcontrib><creatorcontrib>Donnelly, Ryan F.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of pharmaceutics and biopharmaceutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Anjani, Qonita Kurnia</au><au>Moreno-Castellanos, Natalia</au><au>Li, Yaocun</au><au>Sabri, Akmal Hidayat Bin</au><au>Donnelly, Ryan F.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Dissolvable microarray patches of levodopa and carbidopa for Parkinson’s disease management</atitle><jtitle>European journal of pharmaceutics and biopharmaceutics</jtitle><addtitle>Eur J Pharm Biopharm</addtitle><date>2024-06</date><risdate>2024</risdate><volume>199</volume><spage>114304</spage><epage>114304</epage><pages>114304-114304</pages><artnum>114304</artnum><issn>0939-6411</issn><eissn>1873-3441</eissn><abstract>[Display omitted] Carbidopa and levodopa remain the established therapeutic standard for managing Parkinson’s disease. Nevertheless, their oral administration is hindered by rapid enzymatic degradation and gastrointestinal issues, limiting their efficacy, and necessitating alternative delivery methods. This work presents a novel strategy employing dissolving microarray patches (MAPs) loaded with carbidopa and levodopa, formulated with Tween® 80 to improve their transdermal delivery. The fabricated MAPs demonstrated an acceptable mechanical strength, resisting pressures equivalent to manual human thumb application (32 N) onto the skin. Additionally, these MAPs exhibited an insertion depth of up to 650 µm into excised neonatal porcine skin. Ex vivo dermatokinetic studies could achieve delivery efficiencies of approximately 53.35 % for levodopa and 40.14 % for carbidopa over 24 h, demonstrating their significant potential in drug delivery. Biocompatibility assessments conducted on human dermal fibroblast cells corroborated acceptable cytocompatibility, confirming the suitability of these MAPs for dermal application. In conclusion, dissolving MAPs incorporating carbidopa and levodopa represent a promising alternative for improving the therapeutic management of Parkinson’s disease.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>38663522</pmid><doi>10.1016/j.ejpb.2024.114304</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0002-3732-4899</orcidid><orcidid>https://orcid.org/0000-0003-2481-3164</orcidid><orcidid>https://orcid.org/0000-0002-0766-4147</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0939-6411
ispartof European journal of pharmaceutics and biopharmaceutics, 2024-06, Vol.199, p.114304-114304, Article 114304
issn 0939-6411
1873-3441
language eng
recordid cdi_proquest_miscellaneous_3047941731
source MEDLINE; Elsevier ScienceDirect Journals
subjects Administration, Cutaneous
Animals
Antiparkinson Agents - administration & dosage
Antiparkinson Agents - pharmacology
Carbidopa
Carbidopa - administration & dosage
Dissolving microarray patches
Drug Combinations
Drug Delivery Systems - methods
Fibroblasts - drug effects
Fibroblasts - metabolism
Humans
Levodopa
Levodopa - administration & dosage
Microneedles
Parkinson Disease - drug therapy
Parkinson’s disease
Skin - drug effects
Skin - metabolism
Skin Absorption - drug effects
Swine
Transdermal Patch
title Dissolvable microarray patches of levodopa and carbidopa for Parkinson’s disease management
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T00%3A18%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Dissolvable%20microarray%20patches%20of%20levodopa%20and%20carbidopa%20for%20Parkinson%E2%80%99s%20disease%20management&rft.jtitle=European%20journal%20of%20pharmaceutics%20and%20biopharmaceutics&rft.au=Anjani,%20Qonita%20Kurnia&rft.date=2024-06&rft.volume=199&rft.spage=114304&rft.epage=114304&rft.pages=114304-114304&rft.artnum=114304&rft.issn=0939-6411&rft.eissn=1873-3441&rft_id=info:doi/10.1016/j.ejpb.2024.114304&rft_dat=%3Cproquest_cross%3E3047941731%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3047941731&rft_id=info:pmid/38663522&rft_els_id=S0939641124001309&rfr_iscdi=true